Company_NN
Information_NOMZ
141_CD
ACCOUNTING_GER
POLICIES_NN
Basis_NN
of_PIN
accounting_GER
The_DT
Financial_NN
Statements_NOMZ
are_VPRT [PASS]
prepared_VBN
under_IN
the_DT
historical_JJ
cost_NN
convention_NOMZ
,_,
modified_VBN
to_TO
include_VB
revaluation_NOMZ
to_PIN
fair_JJ
value_NN
of_PIN
certain_JJ
financial_JJ
instruments_NOMZ
as_IN
described_VBN
below_PLACE
,_,
in_PIN
accordance_NN
with_PIN
the_DT
Companies_NN
Act_NN
1985_CD
and_CC
UK_NN
Generally_RB
Accepted_JJ
Accounting_GER
Principles_NN
UK_NN
GAAP_NN
._.
The_DT
following_VBG
paragraphs_NN
describe_VPRT
the_DT
main_JJ
accounting_GER
policies_NN
under_IN
UK_NN
GAAP_NN
,_,
which_WDT [SERE]
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
consistently_RB
._.
New_NN
Accounting_GER
Standards_NN
The_DT
Company_NN
has_VPRT [PEAS]
adopted_VBN
the_DT
following_JJ
accounting_GER
standards_NN
in_PIN
the_DT
year_NN
:_:
Financial_NN
Reporting_GER
Standard_NN
No._NN
._.
Under_IN
FRS_NN
20_CD
,_,
the_DT
Company_NN
is_VPRT [PASS]
required_VBN [SUAV]
to_TO
reflect_VB [PRIV]
share-based_JJ
payments_NOMZ
in_PIN
the_DT
profit_NN
and_PHC
loss_NN
account_NN
._.
In_PIN
the_DT
Companys_NN
case_NN
,_,
share-based_JJ
payments_NOMZ
comprise_VPRT
primarily_RB
share_NN
options_NOMZ
through_PIN
the_DT
AstraZeneca_NN
Savings-Related_NN
Share_NN
Option_NOMZ
Scheme_NN
and_CC
the_DT
AstraZeneca_NN
Share_NN
Option_NOMZ
Plan_NN
._.
The_DT
provisions_NN
of_PIN
FRS_NN
20_CD
have_VPRT [PEAS]
been_VBN [PASS]
applied_VBN
to_PIN
options_NOMZ
granted_VBN [SUAV]
after_IN
7_CD
November_NN
2002_CD
._.
The_DT
adoption_NOMZ
of_PIN
FRS_NN
20_CD
had_VBD
no_SYNE
effect_NN
on_PIN
the_DT
Companys_NN
profit_NN
or_CC
net_JJ
assets_NN
._.
21Events_NN
after_IN
the_DT
Balance_NN
Sheet_NN
Date_NN
FRS_NN
21_CD
._.
The_DT
major_JJ
effect_NN
of_PIN
FRS_NN
21_CD
is_VPRT
to_TO
change_VB
the_DT
approach_NN
to_PIN
dividends_NN
declared_VBN [PUBV]
after_IN
the_DT
balance_NN
sheet_NN
date_NN
in_PIN
respect_NN
of_PIN
the_DT
year_NN
under_IN
review_NN
such_OSUB
that_NULL
these_DEMO
dividends_NN
are_VPRT [SPAU] [PASS]
no_RB
longer_RB
accrued_VBN
for_PIN
in_PIN
the_DT
balance_NN
sheet_NN
._.
As_CONJ
a_NULL
result_NULL
of_PIN
adopting_VBG
FRS_NN
21_CD
,_,
the_DT
Companys_NN
net_JJ
assets_NN
at_PIN
31_CD
December_NN
2004_CD
increased_VBN
by_PIN
$_$
1,061_CD
m._FW
23The_NN
Effects_NN
of_PIN
Changes_NN
in_PIN
Foreign_NN
Exchange_NN
Rates_NN
FRS_NN
23_CD
._.
FRS_NN
23_CD
sets_VPRT
out_PIN
additional_JJ
guidance_NN
on_PIN
the_DT
translation_NOMZ
method_NN
for_PIN
transactions_NOMZ
in_PIN
foreign_JJ
currencies_NN
and_CC
on_PIN
determining_VBG [SUAV] [PRIV]
the_DT
functional_JJ
and_CC
presentation_NOMZ
currencies_NN
._.
The_DT
adoption_NOMZ
of_PIN
FRS_NN
23_CD
had_VBD
no_SYNE
effect_NN
on_PIN
the_DT
Companys_NN
profit_NN
or_CC
net_JJ
assets_NN
._.
25Financial_JJ
Instruments_NOMZ
:_:
Disclosure_NN
and_PHC
Presentation_NOMZ
FRS_NN
25_CD
._.
FRS_NN
25_CD
sets_VPRT
out_PIN
the_DT
requirements_NOMZ
for_PIN
the_DT
presentation_NOMZ
of_PIN [STPR]
,_,
and_ANDC
disclosures_NN
relating_VBG [WZPRES]
to_TO
,_,
financial_JJ
instruments_NOMZ
._.
The_DT
adoption_NOMZ
of_PIN
FRS_NN
25_CD
had_VBD
no_SYNE
effect_NN
on_PIN
the_DT
Companys_NN
profit_NN
or_CC
net_JJ
assets_NN
:_:
disclosures_NN
complying_VBG [WZPRES]
with_PIN
the_DT
requirements_NOMZ
of_PIN
FRS_NN
25_CD
are_VPRT [PASS]
included_VBN
in_PIN
the_DT
Financial_NN
Statements_NOMZ
._.
FRS_NN
26_CD
sets_VPRT
out_PIN
requirements_NOMZ
for_PIN
measurement_NOMZ
,_,
recognition_NOMZ
and_PHC
derecognition_NOMZ
of_PIN
financial_JJ
instruments_NOMZ
._.
The_DT
adoption_NOMZ
of_PIN
FRS_NN
26_CD
had_VBD
no_SYNE
effect_NN
on_PIN
the_DT
Companys_NN
profit_NN
or_CC
net_JJ
assets_NN
._.
FRS_NN
28_CD
sets_VPRT
out_PIN
the_DT
requirements_NOMZ
for_PIN
the_DT
disclosure_NN
of_PIN
corresponding_JJ
amounts_NN
for_PIN
items_NN
shown_VBN [PRIV] [WZPAST]
in_PIN
an_DT
entitys_NN
primary_JJ
financial_JJ
statements_NOMZ
and_CC
the_DT
notes_NN
to_PIN
the_DT
financial_JJ
statements_NOMZ
._.
The_DT
adoption_NOMZ
of_PIN
FRS_NN
28_CD
had_VBD
no_SYNE
effect_NN
upon_PIN
the_DT
Companys_NN
profit_NN
or_CC
net_JJ
assets_NN
._.
Foreign_NN
currencies_NN
Profit_NN
and_PHC
loss_NN
accounts_NN
in_PIN
foreign_JJ
currencies_NN
are_VPRT [PASS]
translated_VBN
into_PIN
US_FPP1
dollars_NN
at_PIN
average_JJ
rates_NN
for_PIN
the_DT
relevant_JJ
accounting_GER
periods_NN
._.
Assets_NN
and_PHC
liabilities_NOMZ
are_VPRT [PASS]
translated_VBN
at_PIN
exchange_NN
rates_NN
prevailing_VBG [WZPRES]
at_PIN
the_DT
date_NN
of_PIN
the_DT
Company_NN
balance_NN
sheet_NN
._.
Exchange_NN
gains_NN
and_PHC
losses_NN
are_VPRT [PASS]
included_VBN
within_PIN
net_JJ
interest_NN
payable_JJ
._.
Taxation_NOMZ
The_NN
charge_NN
for_PIN
taxation_NOMZ
is_VPRT [PASS]
based_VBN
on_PIN
the_DT
result_NN
for_PIN
the_DT
year_NN
and_CC
takes_VPRT
into_PIN
account_NN
taxation_NOMZ
deferred_VBN
because_CAUS
of_PIN
timing_NN
differences_NN
between_PIN
the_DT
treatment_NOMZ
of_PIN
certain_JJ
items_NN
for_PIN
taxation_NOMZ
and_CC
for_PIN
accounting_GER
purposes_NN
._.
Full_JJ
provision_NN
is_VPRT [PASS]
made_VBN
for_PIN
the_DT
effects_NN
of_PIN
these_DEMO
differences_NN
._.
Deferred_JJ
tax_NN
asset_NN
valuation_NOMZ
allowances_NN
are_VPRT [PASS]
made_VBN
where_RB
it_PIT
is_VPRT [BEMA]
more_EMPH
likely_PRED
than_PIN
not_XX0
that_DEMO
the_DT
asset_NN
will_PRMD
not_XX0
be_VB [PASS]
realized_VBN [PRIV]
in_PIN
the_DT
future_NN
._.
These_DEMO
valuations_NOMZ
require_VPRT [SUAV]
judgements_NOMZ
to_TO
be_VB [PASS]
made_VBN
including_VBG
the_DT
forecast_NN
of_PIN
future_JJ
taxable_JJ
income_NN
._.
Deferred_JJ
tax_NN
balances_NN
are_VPRT [PASS]
not_XX0
discounted_VBN
._.
Accruals_NN
for_PIN
tax_NN
contingencies_NN
require_VPRT [SUAV]
management_NOMZ
to_TO
make_VB
judgements_NOMZ
and_PHC
estimates_NN
in_PIN
relation_NOMZ
to_PIN
tax_NN
audit_NN
issues_NN
._.
Tax_NN
benefits_NN
are_VPRT [PASS]
not_XX0
recognized_VBN [PRIV]
unless_COND
the_DT
tax_NN
positions_NOMZ
will_PRMD [SPAU]
probably_RB
be_VB [PASS]
sustained_VBN
._.
Once_TIME
considered_VBN [PRIV]
to_TO
be_VB [BEMA]
probable_PRED
,_,
management_NOMZ
reviews_NN
each_QUAN
material_NN
tax_NN
benefit_NN
to_TO
assess_VB
whether_IN
a_DT
provision_NN
should_NEMD
be_VB [PASS]
taken_VBN
against_PIN
full_JJ
recognition_NOMZ
of_PIN
that_DEMO
benefit_NN
on_PIN
the_DT
basis_NN
of_PIN
potential_JJ
settlement_NOMZ
through_PIN
negotiation_NOMZ
and_CC
or_CC
litigation_NOMZ
._.
Any_QUAN
recorded_VBN
exposure_NN
to_PIN
interest_NN
on_PIN
tax_NN
liabilities_NOMZ
is_VPRT [PASS]
provided_VBN
for_PIN
in_PIN
the_DT
tax_NN
charge_NN
._.
All_QUAN
provisions_NN
are_VPRT [PASS]
included_VBN
in_PIN
creditors_NN
due_JJ
within_PIN
one_CD
year_NN
._.
Investments_NOMZ
Fixed_NN
asset_NN
investments_NOMZ
,_,
including_VBG
investments_NOMZ
in_PIN
subsidiaries_NN
,_,
are_VPRT [PASS]
stated_VBN [PUBV]
at_PIN
cost_NN
and_CC
reviewed_VBN
for_PIN
impairment_NOMZ
if_COND
there_EX
are_VPRT
indications_NOMZ
that_TOBJ
the_DT
carrying_VBG
value_NN
may_POMD
not_XX0
be_VB [BEMA]
recoverable_PRED
._.
Financial_NN
instruments_NOMZ
Loans_NN
and_PHC
receivables_NN
are_VPRT [PASS]
held_VBN [PRIV]
at_PIN
amortised_JJ
cost_NN
._.
Long_JJ
term_NN
loans_NN
payable_JJ
are_VPRT [PASS]
held_VBN [PRIV]
at_PIN
amortised_JJ
cost_NN
._.
Other_JJ
financial_JJ
instruments_NOMZ
,_,
including_VBG
derivatives_NN
,_,
are_VPRT [PASS]
held_VBN [PRIV]
at_PIN
fair_JJ
value_NN
:_:
changes_NN
in_PIN
fair_JJ
value_NN
are_VPRT [PASS]
reflected_VBN [PRIV]
in_PIN
the_DT
income_NN
statement_NOMZ
._.
Contingent_JJ
liabilities_NOMZ
Through_PIN
the_DT
normal_JJ
course_NN
of_PIN
business_NOMZ
,_,
AstraZeneca_NN
is_VPRT [PASS]
involved_VBN
in_PIN
legal_JJ
disputes_NN
,_,
the_DT
settlement_NOMZ
of_PIN
which_WDT [PIRE]
may_POMD
involve_VB
cost_NN
to_PIN
the_DT
Company_NN
._.
Provision_NN
is_VPRT [PASS]
made_VBN
where_RB
an_DT
adverse_JJ
outcome_NN
is_VPRT [BEMA]
probable_PRED
and_CC
associated_VBN
costs_NN
can_POMD
be_VB [PASS]
estimated_VBN [PRIV]
reliably_RB
._.
